Literature DB >> 7200322

Kinetics and sites of destruction of 111Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study.

A D Heyns, M G Lötter, P N Badenhorst, F de Kock, H Pieters, C Herbst, O R van Reenen, H Kotze, P C Minnaar.   

Abstract

Kinetics and quantification of the sites of destruction of 111-Indium-oxine-labeled autologous platelets were investigated in eight patients with idiopathic thrombocytopenic purpura. The mean platelet count was 17 +/- 9 X 10(9)/liter; platelets were separated by differential centrifugation and labeled with 5.6 +/- 2.5 MBq 111In. Whole body and organ 111In-platelet distribution was quantitated with a scintillation camera and a computer-assisted imaging system acquisition matrix. Areas of interest were selected with the computer and organ 111In-radioactivity expressed as a percentage of whole body activity. Mean platelet survival was 49.5 +/- 29.6 hr and the survival curves were exponential. Equilibrium percentage organ 111In-radioactivity was (normal values in parentheses): spleen 33.7 +/- 8.8 (31.1 +/- 10.2); liver 16.1 +/- 9.5 (13.1 +/- 1.3); thorax 22.8 +/- 3.7 (28.2 +/- 5.6). Percentage organ 111In-activity at the time when labeled platelets had disappeared from the circulation was: spleen 44.5 +/- 16.4 (40 +/- 16); liver 16.0 +/- 11.5 (32.4 +/- 7.2); thorax 19.7 +/- 6.0 (17.7 +/- 10.3). Thorax activity corresponds to bone marrow radioactivity. Three patterns of platelet sequestration were evident. Three patients had mainly splenic sequestration, two mainly hepatic sequestration, and three diffuse reticuloendothelial system sequestration with a major component of platelets destroyed in the bone marrow. Splenectomy was performed in two patients. The pattern of 111In-platelet sequestration was not predictive of response of glucocorticoid therapy or indicative of the necessity for splenectomy. Quantitative 111In-labeled autologous platelet kinetic studies provide a new tool for the investigation of platelet disorders.U

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200322     DOI: 10.1002/ajh.2830120209

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

Review 1.  The effect of antiplatelet autoantibodies on megakaryocytopoiesis.

Authors:  Robert McMillan; Diane Nugent
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

Review 2.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

3.  Release of platelets into the circulation induced by gamma globulin treatment in a case of idiopathic thrombocytopenic purpura.

Authors:  K G Schmidt; J W Rasmussen; H Diederichsen; M Ulrich
Journal:  Blut       Date:  1984-01

Review 4.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  [Idiopathic thrombocytopenic purpura (Werlhof disease) and differential diagnosis from other thrombocytopenic hemorrhagic diatheses].

Authors:  Kim B Luley; Thomas Wagner
Journal:  Med Klin (Munich)       Date:  2009-05-15

6.  Prediction of the effect of immunoglobulin therapy in ITP.

Authors:  K Kawasugi; J Matsuda; T Abe
Journal:  Blut       Date:  1989-07

7.  Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.

Authors:  P J Ballem; G M Segal; J R Stratton; T Gernsheimer; J W Adamson; S J Slichter
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

8.  Idiopathic thrombocytopenia, initial illness and long term follow up.

Authors:  R W Walker; W Walker
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

9.  Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Current criteria for patient selection and results.

Authors:  O E Akwari; K M Itani; R E Coleman; W F Rosse
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

10.  Treatment of immune thrombocytopenic purpura: focus on eltrombopag.

Authors:  Lawrence Rice
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.